CASI Pharmaceuticals, Inc. Ordinary Shares
CASICASI Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of innovative treatments for cancer, infectious diseases, and other serious conditions. Founded in 2009 and headquartered in Rockville, Maryland, CASI aims to leverage its expertise in drug repurposing and development through strategic collaborations and regulatory approvals, primarily in China and other international markets. The company focuses on bringing both innovative and re-purposed therapies to underserved patient populations worldwide.
Company News
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
HC Wainwright & Co. has decided to maintain its Buy rating of CASI Pharmaceuticals (NASDAQ:CASI) and raise its price target from $10.00 to $12.00. Shares of CASI Pharmaceuticals are trading up 1.33% over the last 24 hours, at $4.56 per share. A move to $12.00 would account for a 163.16% increase from the current share price. About CASI Pharmaceut...
USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Oct. 11. Wheeler Real Estate Investment Trust, ...
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
